---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024983"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:51:48.376528+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Arcellx Q3 net loss $92.9M; initiates pivotal iMMagine-1 study for CART-ddBCMA

## Summary
- Net loss of $92.9M vs $17.1M in Q3 2021, driven by $63.1M non-cash Lonza lease expense.
- Cash, equivalents, and marketable securities of $280.8M as of Sep 30, 2022; funds operations for at least 12 months.
- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA in relapsed/refractory multiple myeloma.
- Longer-term Phase 1 CART-ddBCMA data to be presented at ASH Annual Meeting in December 2022.
- Plan to initiate Phase 1 ARC-SparX trial (ACLX-002) in AML/high-risk MDS by year-end 2022.

## SEC filing metadata
- accession: 0000950170-22-024983
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000095017022024983/0000950170-22-024983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000095017022024983/aclx-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024983
- JSON: https://secwatch.observer/filing/0000950170-22-024983.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024983.txt

## Key facts
- Earnings Releases
  Arcellx, Inc. reported the fiscal quarter ended September 30, 2022 results: net income $92.9 million.
  - Period: the fiscal quarter ended September 30, 2022
  - Net income: $92.9 million
  - Result: reported results
  source text: Net loss was $92.9 million and $17.1 million for the quarters ended September 30, 2022 and 2021, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1786205/000095017022024983/0000950170-22-024983-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.